Publication

Article

Pharmacy Times

November 2012 Cough & Cold
Volume78
Issue 11

From Conception to Delivery: A Pharmacist-Focused Review of Recent Advances in Prenatal Supplements

This activity is supported by an educational grant from vitaMedMD, LLC.

From Conception to Delivery: A Pharmacist-Focused Review of Recent Advances in Prenatal Supplements

Mary M. Bridgeman, PharmD, BCPS, CGP

Clinical Assistant Professor Ernest Mario School of Pharmacy Rutgers, The State University of New Jersey Piscataway, New Jersey Internal Medicine Clinical Pharmacist Robert Wood Johnson University Hospital New Brunswick, New Jersey

Kavitha S. Dalal, PharmD

Pharmacy Field Manager Clinical Adjunct Professor Ernest Mario School of Pharmacy Rutgers, The State University of New Jersey Piscataway, New Jersey

Disclosures

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty: Mary M. Bridgeman, PharmD, BCPS, CGP, and Kavitha S. Dalal, PharmD

Pharmacy Times Office of Continuing Professional Education (PTOCPE) Planning Staff: Judy V. Lum, MPA, and Elena Beyzarov, PharmD

Pharmacy Times Editorial Staff: Jennifer Whartenby and David Allikas

Educational Objectives

Upon completion of this educational activity, participants should be able to:

  • Review updated recommended daily allowances for vitamins, minerals, and other nutrients in pregnancy.
  • Examine the similarities and differences of available OTC and prescription prenatal supplements.
  • Discuss prenatal supplement requirements for special patient populations.
  • Explore the pharmacist's role in educating patients and prescribers on the differences between available prenatal supplements and counseling on the importance of patient adherence.

Target audience:

Pharmacists

Type of activity:

Knowledge

Release date:

November 5, 2012

Expiration date:

November 5, 2014

Estimated time to complete activity:

2 hours

Fee:

This lesson is free online

Click here to view this activity.

Related Videos
Practice Pearl #1 Active Surveillance vs Treatment in Patients with NETs